AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2187791
Drug: Sulphaphenazole 1
RxNorm normalized name: Sulphathiazole
DrugBank: Sulfathiazole (DB06147)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulphaphenazole 1 g 12 hourly by mouth x 10 days
Trial: 2187791
Drug: Inj streptomycin
RxNorm normalized name: streptomycin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inj streptomycin 1 g intramuscularly daily with sulphaphenazole 1 g 12 hourly orally x 10 days
Trial: 2187791
Drug: trimethoprim 200
RxNorm normalized name: trimethoprim 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trimethoprim 200 mg 12 hourly by mouth x 7‐10 days
Trial: 2187791
Drug: erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: erythromycin 500 mg 6 hourly orally x 7‐10 days
Trial: 30813125
Drug: Conventional pulmonary
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pulmonary rehabilitation treatments (pursed lips breathing and abdominal breathing training)
Trial: 26125924
Drug: Conventional perioperative
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional perioperative treatment
Trial: 23414174
Drug: Personal Concerns
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal Concerns Inventory plus treatment as usual
Trial: 21717884
Drug: Travoprost 0.004%/Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004%/Timolol 0.5% fixed combination
Trial: 21717884
Drug: Latanoprost 0.005%/Timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005%/Timolol 0.5% fixed combination
Trial: 21717884
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice a day
Trial: 19366826
Drug: Cetuximab (Erbitux)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab (Erbitux) in monotherapy or in combination with irinotecan
Trial: 15014018
Drug: High-dose IFN-alpha
RxNorm normalized name: IFN .ALPHA.-1B
DrugBank: Interferon alfa-1b (DB18522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose IFN-alpha 2b (HDI)
Trial: 11245347
Drug: Associated administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Associated administration
Trial: 9758295
Drug: Cerebrospinal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrospinal fluid magnesium (CSF Mg+2) levels
Trial: 9758295
Drug: Serum magnesium
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum magnesium (serum Mg+2) levels
Trial: 7805677
Drug: Mean power
RxNorm normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mean power at 4 mmol.l-1 [la-]b
Trial: 2647819
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol (180 micrograms, four times a day)
Trial: 2647819
Drug: Albuterol powder
RxNorm normalized name: albuterol Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol powder (200 micrograms, four times a day)
Trial: 26467414
Drug: Adjunctive omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive omega-3 fatty acid supplementation
Trial: 26467414
Drug: Adjunctive omega-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive omega-3 fatty acids
Trial: 21932934
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IPL and radio frequency (RF)
Trial: 18242894
Drug: Topical DHEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical DHEA (1%)
Trial: 14640494
Drug: SP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP plus paracetamol
Trial: 8855148
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate treatment (various doses)
Trial: 1610422
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg ranitidine
Trial: 24345793
Drug: Levothyroxine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (300 μg/d)
Trial: 18595436
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg for 5 days)
Trial: 11863118
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide 50 mg/m2 for 21 consecutive days every 4 weeks for three courses
Trial: 11863118
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (observation)
Trial: 27053275
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drugs (AP)
Trial: 2076391
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg nifedipine/day
Trial: 7030354
Drug: GABA (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA (12 tablets, 3 g daily for 8 weeks)
Trial: 7030354
Drug: Pyrithioxine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrithioxine (3 tablets, 600 mg daily for 8 weeks)
Trial: 30761961
Drug: Whole grain
RxNorm normalized name: Whole grain barley
DrugBank: Barley (DB10506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole grain diet (120 g of bread made with whole flour daily)
Trial: 25529309
Drug: Extended haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended haemodialysis (≥24 h weekly)
Trial: 25529309
Drug: Standard haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard haemodialysis (12-18 h weekly)
Trial: 22143010
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 μg and propofol 0.5 mg/kg (group P)
Trial: 22143010
Drug: Fentanyl 50
RxNorm normalized name: fentanyl 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 50 μg and etomidate 0.1 mg/kg (group E)
Trial: 17182429
Drug: Strengths Oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengths Oriented Family Therapy (SOFT)
Trial: 8370866
Drug: Short-term psychological
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term psychological treatments
Trial: 29533038
Drug: Arthroscopy-guided core
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arthroscopy-guided core decompression and bone grafting combined with selective arterial infusion
Trial: 29533038
Drug: Percutaneous core
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous core decompression combined with selective arterial infusion
Trial: 26254196
Drug: Palmaria palmata-enriched
RxNorm normalized name: PALMARIA PALMATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmaria palmata-enriched bread (5 g/day)
Trial: 16803603
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (omeprazole, amoxicillin, and clarithromycin)
Trial: 14709953
Drug: Modafinil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100 to 400 mg/d for 4 weeks)
Trial: 11281824
Drug: Neuroprotective agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroprotective agents (specific agents not mentioned)
Trial: 8142099
Drug: 1.5% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% lidocaine with epinephrine 3.75 micrograms/ml (Group A)
Trial: 8142099
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with epinephrine 5 micrograms/ml (Group B)
Trial: 3147196
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate inhaled at maximum flow rate (V1)
Trial: 3147196
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate inhaled at 100 l.min‐1 (V2)
Trial: 3147196
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate inhaled at 50 l.min‐1 (V3)
Trial: 29951734
Drug: Umeclidinium/Vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 µg
Trial: 23992191
Drug: Misoprostol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (doses not specified)
Trial: 20406224
Drug: Rupatadine 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rupatadine 100 mg
Trial: 12660685
Drug: Sarpogrelate in
RxNorm normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarpogrelate in addition to aspirin and ticlopidine
Trial: 30284585
Drug: Remifentanil (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (1 μg/kg prior to induction, 0.05-0.5 μg/kg/minute during maintenance)
Trial: 30284585
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg prior to induction, 0.2-0.7 μg/kg/hour during maintenance)
Trial: 18547903
Drug: Once-daily regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily regimen of efavirenz, extended-release stavudine, and lamivudine (QD arm)
Trial: 18547903
Drug: Existing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing therapy (BID+ arm)
Trial: 12849809
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 300 IU rFSH
Trial: 12849809
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 300 IU rFSH
Trial: 9032569
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no therapy other than calcium)
Trial: 2007040
Drug: Midazolam (4.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (4.2 +/- 1.4 mg loading dose; 8.6 +/- 5.4 mg/h maintenance infusion)
Trial: 2007040
Drug: Propofol (69
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (69 +/- 23 mg loading dose; 265 +/- 185 mg/h maintenance infusion)
Trial: 6812849
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1200 mg flumequine orally
Trial: 6812849
Drug: Two-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose regimen of 1200 and 800 mg flumequine
Trial: 6812849
Drug: Three-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose regimen of 1200, 800, and 800 mg flumequine (six hours apart)
Trial: 30874754
Drug: Antiarrhythmic medication
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic medication (n=76)
Trial: 24601726
Drug: High fructose
RxNorm normalized name: High Fructose Corn Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fructose (HF; 80 g/d)
Trial: 24601726
Drug: Medium fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medium fructose (MF; 40 g/d)
Trial: 24601726
Drug: High sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High sucrose (HS; 80 g/d)
Trial: 24601726
Drug: High glucose
RxNorm normalized name: ONE TOUCH HIGH GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High glucose (HG; 80 g/d)
Trial: 17461312
Drug: Immunonutrition group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition group (oral supplementation for five days before and five days after surgery with 900 mL/day of a formula enriched with arginine, gamma‐3‐fatty acid and RNA + liquid diet ad libitum on one and two postoperative day and then solid food)
Trial: 17461312
Drug: Conventional group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional group (no artificial nutrition before and after surgery, on one and two postoperative day intravenous solution of 5% glucose and electrolytes and then normal diet)
Trial: 15214299
Drug: Calcium 0.5
RxNorm normalized name: CALCIUM 0.55 ORAL TABLET [Restoration Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium 0.5 g/d and placebo
Trial: 8822046
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg t.i.d. for one week)
Trial: 1456855
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (9.98 mmol [400 mg] of elemental calcium) three times daily with meals for 6 weeks
Trial: 6390462
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg nicotinic acid alone per day for 30 days
Trial: 6390462
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg nicotinic acid plus 60,000 U retinol and 140 mg tocopherols per day for 30 days
Trial: 23937282
Drug: Amitriptyline or
RxNorm normalized name: amitriptyline Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline or Nortriptyline (as monotherapy or adjuvant therapy)
Trial: 15888513
Drug: Antipsychotic exposed
RxNorm normalized name: lactose, x-ray exposed (1000 rad)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic exposed (< 12 weeks)
Trial: 12766094
Drug: nateglinide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nateglinide (120 mg a.c.) added to rosiglitazone monotherapy (8 mg q.d.)
Trial: 12766094
Drug: placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo added to rosiglitazone monotherapy
Trial: 8918486
Drug: Concurrent cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent cisplatin 100 mg/m2 at 2-week intervals for three cycles with pelvic radiation
Trial: 8918486
Drug: Radiation without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiation without chemotherapy (Control)
Trial: 29097225
Drug: Single-dose miconazole
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose miconazole suppository
Trial: 29097225
Drug: Multiple-dose miconazole
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple-dose miconazole suppository
Trial: 29097225
Drug: Multiple-dose miconazole
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Multiple-dose miconazole cream
Trial: 18630487
Drug: Preoperative immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative immunotherapy with IL-2 (12 MIU/day SC for 3 consecutive days)
Trial: 18630487
Drug: Preoperative immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative immunotherapy with IL-2 plus surgery
Trial: 16052765
Drug: Adper Prompt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adper Prompt L-Pop/Z100 (3M ESPE)
Trial: 12193491
Drug: Intrathecal sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal sufentanil 50 micro g and morphine 500 micro g
Trial: 10063812
Drug: Creatine (C:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (C: 25 g X d(‐1) for 5 d)
Trial: 7734252
Drug: Ephedrine alone
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine alone (0.2 mg kg‐1 bolus followed by 0.5 mg kg‐1 h‐1 infusion)
Trial: 7734252
Drug: Ephedrine and
RxNorm normalized name: Ephedrine and guaifenesin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine and colloid (polygeline, Haemaccel) 8 ml kg‐1
Trial: 1791077
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with cefotaxime
Trial: 31245333
Drug: OtoClear® Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OtoClear® Spray Wash Kit
Trial: 19291114
Drug: Maggot debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maggot debridement therapy (MDT) with Lucilia cuprina
Trial: 1633839
Drug: Conventional injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional injection of glucagon (1 mg)
Trial: 1633839
Drug: Glucagon injection
RxNorm normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon injection with CGRP (10 nmole)
Trial: 1633839
Drug: Glucagon injection
RxNorm normalized name: glucagon Injection
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Glucagon injection using a multihole 'sprinkler' needle
Trial: 6405428
Drug: Intravenous d-amphetamine
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous d-amphetamine sulphate (15 mg)
Trial: 6405428
Drug: Oral d-amphetamine
RxNorm normalized name: amphetamine / dextroamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral d-amphetamine sulphate (15 mg)
Trial: 31492766
Drug: 1 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ppm of EGF ointment
Trial: 31492766
Drug: 20 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ppm of EGF ointment
Trial: 28079557
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion (20 μg kg‐1 min‐1)
Trial: 25500486
Drug: Crushed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor tablets administered orally
Trial: 25500486
Drug: Crushed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor tablets administered via nasogastric tube
Trial: 25500486
Drug: Whole ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Whole ticagrelor tablets administered orally
Trial: 25500486
Drug: Crushed ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crushed ticagrelor tablets (both methods)
Trial: 19660002
Drug: Udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 200 mg oral dose under fasting conditions
Trial: 19660002
Drug: Udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 200 mg oral dose after a low-fat meal
Trial: 19660002
Drug: Udenafil 200
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 200 mg oral dose after a high-fat meal
Trial: 15462701
Drug: Symbicort adjustable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort adjustable maintenance dosing plan (SAMD) - budesonide/formoterol 1-4 inhalations twice daily depending on symptoms
Trial: 15462701
Drug: Symbicort fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort fixed dosing - 2 inhalations twice daily
Trial: 9757853
Drug: Hydrocortisone (13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (13 mg/m2 every morning and 3 mg/m2 every afternoon for approximately 12 weeks)
Trial: 7818065
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with intravenous pethidine
Trial: 7818065
Drug: Nurse-controlled pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-controlled pethidine infusions
Trial: 2967622
Drug: 0.9 mg
RxNorm normalized name: estradiol 0.9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 mg Zoladex
Trial: 2967622
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg Zoladex
Trial: 2967622
Drug: 3.6 mg
RxNorm normalized name: menthol 3.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg Zoladex
Trial: 29544738
Drug: Cromolyn sodium
RxNorm normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cromolyn sodium (100 mg for ages 2-11, 200 mg for ages 12-17)
Trial: 26354560
Drug: Blood Volume
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Volume Monitoring (BVM) treatment
Trial: 26354560
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BVM treatment)
Trial: 22527264
Drug: Human rights‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human rights‐based intervention approach with four dialogical meetings focused on medication intake scenes
Trial: 20184444
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of lornoxicam